Skip to Content
  • Home
  • People
  • Advancing Sphingolipid Enzyme Targeting as a Disease-Modifying Strategy for Friedreich’s ataxia: Extended Preclinical Evaluation

Advancing Sphingolipid Enzyme Targeting as a Disease-Modifying Strategy for Friedreich’s ataxia: Extended Preclinical Evaluation

Funder: Friedreich's Ataxia Research Alliance
Duration: October 2026 -

People

Name Telephone Email Office
Dr Sara Anjomani Virmouni Dr Sara Anjomani Virmouni
Senior Lecturer in Biomedical Sciences
(Principal investigator)
T: +44 (0)1895 268165
E: sara.anjomanivirmouni@brunel.ac.uk
 +44 (0)1895 268165 sara.anjomanivirmouni@brunel.ac.uk